Appendix Table 2.
Unadjusted Population Characteristics for Initial Use Antihypertensive Primary Care Patients by Treatment Strategy
| Characteristic | FDC* (n=795) | FEC* (n=712) | Mono* (n=7,169) | p values† |
|---|---|---|---|---|
| Gender (female), n (%) | 373 (46.9) | 442 (62.1) | 3,878 (44.7) | <0.001 |
| Age at index (y), mean (SD) | 52.9 (12.6) | 61.9 (12.9) | 53.8 (13.4) | <0.001 |
| BMI (kg/m2), mean (SD) | 31.9 (7.2) | 30.4 (6.9) | 30.6 (6.8) | <0.001 |
| Index systolic (mm Hg), mean (SD) | 153.8 (16.5) | 147.8 (16.4) | 148.2 (14.7) | <0.001 |
| Index diastolic (mm Hg), mean (SD) | 94.3 (11.1) | 85.9 (12.2) | 90.4 (10.6) | <0.001 |
| CKD, n (%) | 54 (6.8) | 188 (26.4) | 612 (7.1) | <0.001 |
| Diabetes, n (%) | 66 (8.3) | 168 (23.6) | 1,091 (12.6) | <0.001 |
| Hyperlipidemia, n (%) | 251 (31.6) | 209 (29.4) | 2,381 (27.4) | 0.09 |
| Hypertension, n (%) | 594 (74.7) | 456 (64.0) | 4,280 (49.3) | <0.001 |
| Follow-up duration (months), mean (SD) | 6.2 (3.8) | 6.7 (3.9) | 6.3 (3.9) | 0.02 |
| Number of clinic visits, mean (SD) | 3.0 (2.8) | 4.2 (3.8) | 3.9 (3.4) | <0.001 |
*
Abbrev: FDC, fixed-dose combinations; FEC, free-equivalent combinations; Mono, monotherapy.
†
P values were from analysis of variance (ANOVA) or logistic regression and test the overall effect across the three treatment strategies.